Did MEI/Kyowa Kirin Beat The PI3K Tolerability Trap?
Zandelisib Shows Unexpectedly Positive Data
PI3K-delta inhibitors have often suffered from safety and tolerability issues, but Phase II data show higher efficacy and lower discontinuation rates for zandelisib than others in the class.
You may also be interested in...
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.
Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.
A first-in-class PI3K/CK1 epsilon inhibitor, Ukoniq was approved by the US FDA for two types of lymphoma.